Regulatory

September 19, 2025

Positive 16-week Phase 3 Data of Izokibep in Hidradenitis Suppurativa Presented at EADV 2025

Solna, Sweden, September 19, 2025. Affibody AB (“Affibody”) today announced positive 16-week data from a global Phase 3 study of izokibep in hidradenitis suppurativa (HS) that was presented at...

Read more

Regulatory

September 11, 2025

Positive 16-week Phase 3 Data of Izokibep in Hidradenitis Suppurativa to be Presented at EADV 2025 Late Breaking Session

Solna, Sweden, September 11, 2025. Affibody AB (“Affibody”) today announced that positive 16-week data from a global Phase 3 study of izokibep in hidradenitis suppurativa (HS) will be presented...

Read more

Regulatory

June 13, 2025

Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study

Solna, Sweden, June 13, 2025. Affibody’s licensee Rallybio Corporation (Rallybio) has announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, an innovative, once-weekly,...

Read more

Regulatory

December 10, 2024

Affibody’s Licensee ACELYRIN Announces Top-line Results for Izokibep in Uveitis

Stockholm, Sweden, December 10, 2024. Affibody’s licensee ACELYRIN, INC. today announced that the Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint. Izokibep...

Read more

Regulatory

August 13, 2024

Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep

• Phase 3 trial of izokibep in patients with hidradenitis suppurativa met primary endpoint of HiSCR75 at week 12, as well as the key secondary endpoints of HiSCR90 and...

Read more

Regulatory

May 16, 2024

Report from Annual General Meeting in Affibody Medical AB (publ)

Solna, Sweden, May 16, 2024 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Read more

Regulatory

March 26, 2024

First gastroesophageal cancer patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, March 26, 2024. Affibody AB (“Affibody”) today announced that the first patients with gastroesophageal cancer have been dosed in a Phase 2 clinical basket study of the...

Read more

Regulatory

March 11, 2024

Affibody’s Partner ACELYRIN Announces Positive Top-line Results for Izokibep in Psoriatic Arthritis and Long-Term Clinical Benefits in Hidradenitis Suppurativa

Phase 2b/3 psoriatic arthritis clinical trial met the primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance. Robust responses were achieved for ACR70, PASI100, ACR50/PASI100,...

Read more

Regulatory

December 20, 2023

Affibody’s Licensee Rallybio Announces Preliminary Phase 1 MAD Data for RLYB116

Solna, Sweden, December 20, 2023. Affibody’s licensee Rallybio Corporation (Rallybio) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected...

Read more